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Obesity increases the risk of clinical decompensation in cirrhosis, possibly by increasing 
portal pressure. Whether weight reduction can be safely achieved through lifestyle 
changes (diet and exercise) in overweight/obese patients with cirrhosis, and if weight 
loss reducesportal pressure in this setting is unknown. This prospective, multicentric, 
uncontrolled pilot study enrolled patients with compensated cirrhosis, portal 
hypertension (hepatic venous pressure gradient, HVPG≥ 6mmHg) and body mass index 
(BMI)≥26 Kg/m2 in an intensive 16-week lifestyle intervention program (personalized 
hypocaloric normoproteic diet and 60 min/wk of supervised physical activity). We 
measured HVPG, body weight and composition, adipokines, health-related quality-of-
life and safety data prior and after the intervention. Changes in HVPG and body weight 
were pre-defined as clinically relevant if ≥10% and ≥5%, respectively. Safety and body 
weight were re-assessed after 6 months. 60 patients were included and 50 completed the 
study (56±8 y/o; 62% male; NASH etiology 24%; BMI 33.3±3.2Kg/m2; Child A 92%; 
HVPG ≥10 mmHg 72%). Lifestyle intervention significantly decreased body weight 
(average -5.0±4.0 Kg; p<0.0001), by ≥ 5% in 52% and ≥10% in 16%.  HVPG also 
significantly decreased (from 13.9±5.6 mmHg to 12.3±5.2 mmHg, p<0.0001), by ≥10% 
in 42% and ≥20% in 24%. A ≥10% body weight loss was associated with a greater 
decrease in HVPG (-23.7±19.9% vs. -8.2±16.6%,p=0.024). No episodes of clinical 
decompensation occurred. Weight loss achieved at 16-wks was maintained at 6-month; 
Child and MELD scores did not change. 
Conclusions. 16-weeks of diet and moderate exercise were safe and reduced body 
weight and portal pressure in overweight/obese patients with cirrhosis and portal 
hypertension.  
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Obesity and obesity-associated conditions are growing health problems worldwide. In 
recent prospective studies over 70% of patients with compensated cirrhosis were either 
overweight or obese (1, 2), similarly to the general population (1, 2). Besides being a 
cause of chronic liver disease per se, obesity worsens the prognosis of patients with 
compensated cirrhosis induced by other causes (1, 2), and the risk of first clinical 
decompensation of cirrhosis is approximately three times higher in obese patients as 
compared to normal weight ones (1, 2). The mechanisms explaining this clinical 
association have not been clarified yet, but appears to involve a progressive increase in 
portal pressure (1). Since portal hypertension constitutes the pathophysiological basis of 
most complications of cirrhosis (3), therapeutic measures for patients with cirrhosis 
should be aimed at reducing portal pressure. In particular, non-pharmacological 
strategies to improve portal hypertension would be highly desirable(4).  
Weight loss ≥ 5-7% obtained by combining hypocaloric diet and exercise is an effective 
treatment for obesity-related chronic liver disease (non-alcoholic fatty liver disease, 
NAFLD)(5, 6); furthermore, such a relatively modest weight loss is sufficient to 
determine clinically relevant improvements in other clinical scenarios, such as a 
reduction of cardiovascular risk in overweight and obese patients with type 2 diabetes 
(7). Mechanisms involved include improvement in insulin-resistance and reduction in 
proinflammatory, profibrogenic and pro-angiogenic adipokines/cytokines. Some of 
these cytokines, such as Leptin, have been suggested to modulate portal hypertension in 
cirrhosis; we have recently shown that leptin receptor blockade decreased hepatic 
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vascular resistance and portal pressure in experimental cirrhosis (8), which supports the 
view that excessive leptin release might exacerbate portal hypertension in obese 
cirrhotics.  
However, the safety of weight loss in patients with cirrhosis has not been fully 
established yet, and there is concern regarding possible deleterious effects on liver 
function mediated by worsening of sarcopenia (9). 
Given the above mentioned evidence, we hypothesized that an intensive life-style 
intervention consisting in a personalized and monitorized hypocaloric diet and 
supervised moderate physical exercise would result in improvement in portal 
hypertension in patients with compensated cirrhosis and overweight or obesity; this 
effect would be mediated by a decrease in intrahepatic vascular resistance. Furthermore, 
intensive life-style intervention would be associated with a modest body weight loss 
without adverse events on liver function.  
The present study was aimed at testing these hypotheses.  
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Selection of Patients  
From September 2011 through November 2013 we conducted a prospective, 
multicentric, pilot study in six University Hospitals in Spain. The study was registered 
in ClinicalTrials.gov (registration number: NCT 01409356). 
All the following inclusion criteria had to be fulfilled: 
- Liver cirrhosis of any atiology diagnosed by histology or by clear clinical, laboratory 
and imaging criteria 
- compensated stage or single episode of variceal bleeding > 6 months before inclusion, 
provided this was not associated with ascites or any other complication 
-  Child-Pugh class A or B ≤ 8 points 
- HVPG ≥ 6 mmHg  
- BMI≥26 Kg/m
2
, stable in the last 6 months (BW changes < 3 Kg were considered 
acceptable)  
-  Age 18-75 years  
Safety considerations: since exercise can be associated with acute increases in portal 
pressure (10), all included patients with gastroesophageal varices had to be on proper, 
stable primary or secondary prophylaxis of variceal bleeding. An electrocardiogram was 
obtained in all patients on the screening visit. 
Any of the following was considered exclusion criteria: previous or ongoing ascites; 
previous or ongoing jaundice, severe bacterial infections leading to hospitalisation, 
porto-systemic encephalopathy, hepatocellular carcinoma. Active alcohol consumption 
(minimum abstinence: 6 months) untreated large gastroesophageal varices; complete 
portal vein thrombosis; Child-Pugh Score >8; transjugular intrahepatic porto-systemic 
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shunt; previous liver transplantation; ischemic heart disease or electrocardiographic 
signs of ischemic heart disease; severe orthopaedic problems limiting the possibility to 
exercise.  
Ethical aspects 
This study, coordinated by the Hospital Clinic in Barcelona, was approved by the Ethics 
Committee of each participating center. The nature of the study was explained to the 
patients, and a written informed consent was obtained in each case, according to the 
principles of the Declaration of Helsinki (revision of Edinburgh 2000). 
Endpoints 
The main endpoints of this study were the changes in body weight and in HVPG after 
16 weeks of intensive lifestyle intervention. 
Secondary endpoints included safety (liver-related events and changes in liver function 
tests), and changes in body composition, oxygen consumption, adipokines and health-
related quality of life after 16 weeks of lifestyle intervention. 
Variables of the study  
All the variables object of the study were assessed on inclusion and after completing 16 
weeks of lifestyle intervention. 
A diagram illustrating the study design is provided in Supplementary Figure 1. 
Clinical and laboratory data. Clinical history data included etiology of liver disease, 
presence of esophageal varices and ongoing treatment with non selective beta-blockers, 
presence of diabetes, arterial hypertension, and dyslipemia, and concomitant 
medication; hemodynamic assessment included simple data on systemic hemodynamics: 
heart rate, systolic, diastolic and mean pressure (evaluated by standard 
sphygmomanometry after 10 minute rest on the day of the visit); laboratory data 
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included standard tests (hemoglobin, leucocytes count, platelet count, AST/ALT, GGT, 
Alk. Phosphatase, Creatinine, Bilirubin, Albumin, Glucose, Sodium, Potassium). 
Plasma and serum samples were obtained and stored for adipokines, adipocytokines and 
cytokines testing. Interleukin 6 (IL-6); Interleukin 8 (IL-8), Interleukin 1beta (IL-1b), 
Insulin, Leptin, Hepatocyte Growth Factor (HGF), Tumor Necrosis Factor alpha (TNF-
a), Nerve Growth Factor (NGF) and Monocyte Chemoattractant Protein 1 (MCP-1) 
were simultaneously measured on these samples by Immunoessay  (see Suppl. 
Methods). 
Hepatic Venous Pressure Gradient was measured according to the international 
recommendations as previously described (see Suppl. Methods)(11).  
Indocianine green clearance, extraction index and hepatic blood flow were measured in 
a subgroup of 23 patients, included in two of the participating centers, as previously 
described (12) (see Suppl. Methods). 
Nutritional status assessment was made analyzing the dietary habits of the patients; 
anthropometric measurement included weight, height, waist circumference and fat mass 
(bioelectrical impedance analysis, BIA) (see Suppl. Methods).  
Physical activity assessment. Patients were asked specific questions regarding whether 
they used to perform exercise, and in case they did regarding its kind, intensity and 
duration; specific questions regarded sedentarism (number of hours spent watching TV 
or computer). A subgroup of patients (n=24, all included in Barcelona) underwent 
assessment of maximal oxygen uptake (VO2max) by a standard Bruce’s test based on 
progressive effort on a treadmill at baseline and 16-wks. An indirect estimation of 
maximal oxygen uptake was used in patients in whom Bruce’s test was not available 
(13). 
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Quality of life. A liver-disease specific validated questionnaire was used (CLDQ, 
Spanish edition)(14). Patients filled-in autonomously the questionnaire, which contains 
questions regarding 6 domains of quality of life (abdominal symptoms, fatigue, 
systemic symptoms, activity, emotional function, worry). Score for every question is an 
entire number between 0 (the worst possible) and 7 (the best possible). 
Lifestyle intervention 
An intensive lifestyle intervention was initiated within one week of the baseline HVPG 
measurement. It consisted in 16-week of caloric restriction (diet) and exercise, which 
are shortly detailed below (see also the Supplementary Methods). 
Diet: consisted in a tailored reduction in caloric intake of 500-1000 kCal per day. 
Protein intake was maintained between 20 and 25% of the total intake in order to reduce 
the risk of muscle mass loss, but within 0.8 g/Kg of ideal BW (calculated for a BMI=25 
Kg/m
2
) per day. Diet was balanced in order to be not ketogenic, and as varied as 
possible. Carbohydrates accounted for 45-50% fo total kCal, fat content was maintained 
< 35% of total kCal and 20 g of alimentary fiber was also recommended. No alcohol 
was allowed.  
Physical activity: On the same week of nutritional intervention initiation, patients began 
exercising. Exercise was supervised by two professional trainers (PTs), one for patients 
included in Barcelona and one for patients included in Madrid. One weekly 60 minutes 
session of moderate exercise in small groups (1-5 patients) was conducted. Every 
session consisted in 10 minutes of warm up, 40 minutes of aerobic and strength 
exercising routine, and 10 minutes of cooling down. Exercise routine was chosen by the 
trainers avoiding abdominal workouts/pump, and tailored to a perceived exertion of 4-
5/10 (Visual Analogue Scale) or 10-12 Borg Rating of Perceived Exertion Scale. 
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In addition, all patients were instructed to increase their daily standard physical activity. 
The total amount of physical activity over the 16 weeks of the study was estimated by 
calculating the metabolic equivalents of tasks (METs) (15). 
Clinical follow-up: once a month the patient was seen by one of the participating 
hepatologists in order to assess changes in the clinical status, record any relevant event 
and changes of medication occurring during the study. An extra visit was scheduled 6 
months after the completion of the 16-weeks lifestyle intervention in order to evaluate 
medium-term safety and body weight. 
 
Sample size 
According to previous data in patients with cirrhosis, changes in HVPG were pre-
defined as clinically relevant if ≥10% (16). As for changes in body weight, we pre-
defined it as clinically relevant if ≥5% (17). Based on data obtained in non-cirrhotic 
patients with obesity (18), we assumed that a maximum of 50% of the included patients 
would be able to decrease body weight to this extent. Since no data regarding changes in 
HVPG associated with body weight changes were available previous to this study, we 
hypothesized that 30% of patients showing a clinically relevant weight loss would also 
show a clinically relevant reduction in HVPG. With these assumptions, accepting an 
alpha error of 0.05, a beta error of 0.20 and 10% subject loss during the study, using the 
Fischer exact test, the inclusion of 60 patients was required to demonstrate the existence 
of a clinical association between weight loss and reduction in HVPG. 
Statistical analysis 
A minimum attendance of 30% to the lifestyle intervention visits was required to enter 
the final analysis. Quantitative variables are expressed as mean and standard deviation 
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(SD), whereas qualitative variables as absolute and relative frequencies. Comparisons 
between groups were made by the Student’s T test, Mann-Whitney test or Kruskall-
Wallis test, as appropriate for quantitative variables, and by Chi square, Fisher’s test for 
the qualitative variables. Within each group continuous variables were compared using 
the Student's t test for paired data. Correlations between variables were computed using 
the Pearson’s or Spearman Rho coefficient, when appropriate. Statistical analysis was 
performed with SPSS 22.0 package (SPSS Inc., Chicago, IL USA). The α value was set 
at 0.05. All p-values are two-sided.  
All authors had access to the study data and reviewed and approved the final 
manuscript. 
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60 patients were considered eligible and signed the informed consent; 3 of them were 
not put on the lifestyle intervention program due to HVPG < 6 mmHg (inclusion error). 
Among the 57 patients who initiated the program, 7 either did not complete it 
(withdrawal of consent, n= 2; suspicion/identification of hepatocellular carcinoma on 
ultrasound during the study, n=2) or did not fulfil the minimal pre-defined attendance 
criteria (n=3). 
50 patients successfully completed the study and were included in the final analysis. 
Their main characteristics are summarised in Table 1. The attendance to physical 
activity sessions and nutritional therapy session was high, respectively 88% and 84%. 
Adherence to calory intake was 75±14%. 
As for non-supervised physical activity, 39/50 patients correctly completed the physical 
activity log over 16 weeks. Among them, 16 engaged in weekly or biweekly exercising 
in addition to walking, while for 23 walking was the only additional exercise. Overall, 
the median cumulative walking/exercising time was 123.7 hours (range: 43 hours- 241 
hours)  and the calculated METs were 400.5 (150.5-1032.9) (Supplementary Table 1). 
Effect of intensive lifestyle intervention on body weight and body composition 
The intensive lifestyle intervention induced a significant decrease in body weight 
(Figure 1; Supp. Figure 2), which was on average ˗5.0 ± 4.0 Kg (p<0.0001); the 
decrease was ≥ 5% (clinically relevant) in 52% of the included population; in 16% 
weight loss was ≥10%. Changes in body weight were similar in the different etiologies 
of cirrhosis: viral: ˗6.7 ± 3.8 Kg (p<0.0001 vs. baseline); alcohol: ˗5.5 ± 4.8 Kg 
(p<0.0001 vs. baseline); NASH: ˗4.1 ± 4.0 Kg (p=0.002 vs. baseline) (Kruskall-Wallis 
test among etiologies: p=0.587). 
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Weight loss was associated with a significant decrease in fat mass, while lean mass did 
not change (Table 2). Body weight loss was maintained after 6 months of follow-up 
(86.2±13.7 Kg at 16-wk vs. 85.6±13.7 Kg after 6 months, p=0.257). At this time-point 
about half of the population refereed to have continued on diet (57%) and exercise 
(53%) after completing the 16 weeks of intensive LS intervention. 
Effect of lifestyle intervention on HVPG 
HVPG significantly decreased after 16-wk of lifestyle intervention (Figure 2, Supp. 
Figure 3), from 13.9±5.6 mmHg to 12.3±5.2 mmHg (p<0.0001). A clinically relevant 
decrease in HVPG (namely ≥10% vs. baseline) was observed in 42% of the included 
population; in 24% HVPG decreased ≥20%. Furthermore, 4 patients with HVPG ≥ 10 
mmHg on inclusion showed a HVPG value < 10 mmHg after 16-wk LS intervention. 
In the subset of 23 patients that had measurements of hepatic blood flow, similarly to 
what observed in the whole included population, there was a significant decrease in 
HVPG (15.7±5.4 mmHg at baseline vs.13.7± 5.1 mmHg at 16 weeks; p=0.015), which 
was not associated with any change in hepatic blood flow (898±520 ml/min at baseline 
vs.  782±382 at 16 weeks; p=0.565), but which was associated with a significant 
improvement in indocyanine green extraction (from 0.54±0.17 to 0.59±0.19; p=0.048). 
These findings suggest that a decrease in intrahepatic vascular resistance contributed to 
the decrease in portal pressure.  
Relation of changes in body weight and in HVPG  
Figure 3 summarises the observed changes in HVPG according to the observed 
reduction in body weight. Overall, there was no statistical correlation between changes 
in body weight and HVPG (R=0.010, p=0.944). However, patients achieving a greater 
reduction in body weight, namely ≥10%, exhibited a greater decrease in HVPG ( 
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˗23.7±19.9% vs. ˗8.2±16.6% decrease in HVPG in those reducing body weight less than 
10%; p=0.024). Interestingly, the 4 patients showing a reduction in HVPG below the 
threshold of 10 mmHg had decreased their body weight ≥ 10%.  
Relation of changes in HVPG and cumulative physical activity during the study period 
This point was addressed in the 39 patients who provided data regarding the amount of 
non-supervised physical activity they carried out over the study period. A more intense 
physical activity, namely above the median of the study group (METs: 400.5 over 16 
weeks; Supplementary Table 1), was associated with a more marked decrease in HVPG: 
-16.7±17.3% in patients above the METs median vs. -5.1±19.9 in patients exercising 
below the METs median; p=0.054. As shown in Table 3, the beneficial effect of 
exercise resulted statistically significant only in patients showing non-clinically relevant 
changes in body weight. These results suggest a possible independent effect of body 
weight reduction and physical activity on portal pressure. 
Relation of changes in HVPG and body weight with other variables 
The presence of diabetes and  a higher fat mass on BIA were associated, respectively, to 
lack of clinically relevant reduction of body weight and to lack of clinically relevant 
reduction of HVPG after the intensive lifestyle intervention (Table 1). Patients with 
diabetes showed a lower change in HVPG as compared to non-diabetic patients (% 
change in HVPG: -5.2±16.7%  vs. -14.7±17.9%; p=0.06).  
HVPG and body weight decreased similarly in patients on non-selective beta-blockers 
(NSBBs) vs. those not taking NSBBs (Table 1). The adherence to diet of patients on 
NSBB was similar to that of patients not on NSBB (median: 73.1% vs. 81.2%, NS), and 
the median hours spent walking/exercising over 16 weeks was similar as well (122±43 
hours vs. 122±53 hours, NS). No differences were seen in the improvement of indirectly 
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assessed maximal aerobic capacity of patients on NSBB (from baseline 28.5±5.3 to 
31.7±5.6 ml/Kg/min after LS intervention, p<0.0001) and not on NSBB (from baseline 
28.3±5.6 to 30.9±6.1 ml/Kg/min after LS intervention, p<0.0001).  
Having experienced or not an episode of variceal bleeding, cirrhosis etiology, severity 
of portal hypertension, presence/absence of arterial hypertension or dyslipidemia did not 
influence these results. Among the baseline variables, on a multivariate analysis 
including fat mass and diabetes, only fat mass remained negatively and independently 
associated with HVPG response to LS intervention (B coefficient - 0.129; p=0.030). 
Changes in insulin, adipokines/adipocytokines and cytokines 
 Most of the tested plasma levels of cytokines, namely IL-1, IL-6, IL-8, HGF, NGF, 
TNFα and MCP1, did not change after the LS intervention. Serum insulin and leptin 
significantly decreased after LS intervention (Table 2), being their decrease greater in 
patients showing a clinically relevant weight loss. Insulin decreased by 33±30% in 
patients with weight loss ≥5% vs. 5±55% in those with weight loss <5% (p=0.043).  As 
a consequence, HOMA decreased from 9.5±9.4 to  6.1±4.8, p=0.015, and QUICKI 
increased from 0.29±0.03 to 0.31±0.04, p=0.008. Similarly, leptin decreased by 
42±25% in patients with weight loss ≥5% vs. 4±43% in those with weight loss <5% 
(p=0.001). Anyhow, changes in cytokines were similar in patients who showed a 
clinically relevant HVPG decrease vs. those who did not. 
Changes in quality of life 
Quality of life significantly improved after LS intervention: global score: 5.5±1.0 vs. 
5.2±1.0 at baseline ( p<0.001). A significant improvement was noticed in all the 
domains of the questionnaire (Supplementary Figure 4); the improvement was 
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particularly evident in patients achieving a clinically relevant weight loss: global score: 
5.7±1.0 vs. 5.3±1.1 at baseline, p<0.0001 (all domains). 
Safety    
None of the patients experienced episodes of clinical decompensation during the 16 
weeks of lifestyle intervention. Child and MELD scores did not change after 16 weeks 
of diet and exercise (Table 2). Adverse event during the 16 weeks of LS intervention 
were few: 1 case of mild pretibial edema, spontaneously disappeared; 1 reported 
worsening of asthma requiring increase in bronchodilators dosage, and 1 episode of 
arthritis due to gout. On the other hand, 4 patients (one on insulin alone, two on insulin 
+ metformin and 1 on metformin alone) required reduction in their medication for 
diabetes and 1 patient stopped spironolactone for disappearance of lower limbs edema. 
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Obesity incidence is increasing dramatically worldwide, and is nowadays common in 
patients with compensated cirrhosis (1, 2). It has been previously shown that obesity has 
a negative impact on the natural history of cirrhosis (1, 2), but very little is known about 
how these two chronic conditions interact. More specifically it is unknown whether 
standard measures correcting obesity, that have a positive effect on many of its 
metabolic and cardiovascular consequences (19), can also improve the course of 
cirrhosis through improving portal hypertension. 
The major finding of this study is that a short (4 months) intensive lifestyle changes 
intervention, consisting in tailored diet and supervised exercise of moderate intensity, is 
able to reduce portal pressure in patients with cirrhosis and overweight or obesity. 
Importantly, the lifestyle intervention proved safe, since no episode of clinical 
decompensation was observed during the study, and liver function tests remained 
unchanged.  
Over 40% of the included patients showed a clinically relevant benefit on portal 
pressure, defined as a decrease in HVPG ≥10% of baseline. Such a decrease has been 
shown to be of clinical relevance preventing ascites in patients on primary prophylaxis 
with non-selective beta-blockers (16), and was associated with a decreased formation of 
varices in compensated portal hypertensive patients without esophageal varices (20). 
Furthermore, the decrease in HVPG was ≥20% of baseline  in a quarter of the included 
patients, a magnitude of reduction that has been associated with a decrease in the 
incidence of all complications of portal hypertension and with improved survival when 
achieved on chronic non-selective beta-blockers(21-23). The amount of weight loss 
showed no linear relationship with the degree of HVPG reduction, suggesting that the 
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mechanisms leading to the reduction in portal pressure are likely complex and may 
differ between patients; however, patients achieving a greater weight loss, namely 
>10% of body weight, also showed a significantly greater HVPG reduction, including 
achieving more frequently a >10% decrease in HVPG and reaching a final HVPG below 
of 10 mmHg (the risk threshold for developing complications from portal hypertension). 
These results might justify recommending a weight loss of at least 10% in this 
population, in order to maximise the likelihood of a clinically relevant benefit on portal 
pressure. As for the possibility of predicting which patients would benefit more from a 
lifestyle intervention, we observed no significant influence of etiology, severity of 
portal hypertension, presence/absence of previous episodes of variceal bleeding and 
presence/absence of arterial hypertension or dyslipidemia; however, the presence of 
diabetes was associated with a lower reduction in body weight and in HVPG, suggesting 
that in this population other approaches should be attempted. Interestingly, a higher fat 
mass on inclusion was associated with lack of clinically relevant reduction of HVPG 
after the intensive lifestyle intervention. This finding is intriguing and points to the 
possibility that adipose tissue mass rather than BMI is important in the modulation of 
portal hypertension. However, it has been previously showed that the study of body 
composition by BIA has limitations in patients with cirrhosis, mostly due to erratic 
measurements in case of water retention (24). Since our population excluded patients 
with previous or ongoing ascites, it is unlikely that water retention could have prevented 
a correct evaluation of the effect of BMI and its changes on portal pressure. 
Patients on NSBBs showed an attendance to exercising and an improvement in maximal 
aerobic capacity similar to that of patients not on NSBBs, consistent to results obtained 
in non-cirrhotic subjects showing that NSBBs do not prevent a training-induced 
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amelioration of VO2 (25). Notably, the positive effect of diet and exercise on HVPG 
was observed also in patients already on NSBBs, confirming that this non-
pharmacological approach leads to an added benefit in cirrhosis. This finding further 
suggests that the mechanism of the reduction in HVPG achieved through the life-style 
intervention differs from that of non-selective beta-blockers (splanchnic 
vasoconstriction)(3). Indeed, it is worth noting that in the subgroup of our patients that 
had measurements of hepatic blood flow before and after life-stile intervention, no 
significant change was observed; a decrease in HVPG in the context of such a lack of 
changes in liver blood flow is another strong argument indicating a decrease in hepatic 
vascular resistance. Also, as discussed below, the positive effect of weight loss on 
insulin resistance and leptin release probably resulted in a fall in hepatic resistance and 
in this way mediated the decrease in HVPG observed after weight loss (8, 26).  
It should be underlined that our study included only patients without ascites and without 
any previous episodes of ascites; this was done to ensure homogeneity of the population 
and to avoid the potential detrimental effect of weight loss in patients that are almost 
invariably sarcopenic (9). On the other hand, it is important to observe that in the 
present study weight loss was not associated to a reduction in lean mass (mostly muscle 
mass), likely due to the protective effect of exercise on muscle mass (27) and of the 
adequate protein intake provided by the tailored diet. Despite further studies in this 
field, our results suggest that in order to avoid worsening or onset of sarcopenia in obese 
patients with cirrhosis in whom body weight reduction is attempted, exercise needs to 
be combined to calorie restriction, and diet macronutrients should include an 
appropriate amount of proteins.  
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Due to the pragmatic design of the study, that included both tailored diet and exercise, 
we cannot answer the question whether the observed effect on HVPG is due to only one 
of them, and regarding the specific role of each of the two components of lifestyle 
intervention. According to data obtained in patients with NAFLD/NASH, the 
combination of diet and exercise is more effective in achieving a significant weight loss, 
but exercise per se seems sufficient to reduce the amount of visceral fat (27). Anyhow, 
in a subgroup of our study population, we observed that a higher amount of hours spent 
exercising during the study period was associated with a more pronounced decrease in 
HVPG, and that exercise may possibly explain HVPG reduction in some patients not 
achieving a clinically relevant weight loss (Figure 3; Table 3). Even if preliminary, our 
data suggests that physical activity per se might modulate portal pressure in cirrhosis. 
The present study has some limitations; some of them are inherent to any exploratory 
pilot study, without randomised allocation to intervention or to a control group. 
Nonetheless, the likelihood that the HVPG spontaneously decreased in the included 
patients is very low, as proved by several studies addressing hemodynamic changes in 
compensated cirrhosis not undergoing etiological treatment. Of note, this study was 
conducted before the new generation of direct antiviral agents for hepatitis C was 
available in Spain. We cannot provide firm data on the molecular mechanisms leading 
to portal pressure decrease; however, our findings lead us to propose that the decrease in 
insulin and in particular of leptin, could mediate changes in portal pressure occurring 
over a relatively short period due to their ability to modulate the intrahepatic vascular 
resistance (Figure 4). Insulin (and insulin-resistance expressed either as HOMA or 
QUICKI indexes) and leptin overall decreased after the lifestyle intervention, and 
markedly decreased in patients who lost ≥10% of body weight. It is worth noting that 
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we have recently reported that leptin-receptor blockade decreases hepatic vascular 
resistance and portal pressure in experimental cirrhosis(8), and that the correction of 
insulin-resistance by metformin has a similar effects (26). This reinforces the view that 
reduced leptin levels and improved insulin-sensitivity through life-style intervention 
may be part of the mechanisms involved in the decrease in HVPG observed in our 
patients. On the other hand, it should be noted that the decrease in insulin and leptin 
levels did not differ between patients showing a ≥10% decrease in the HVPG or not. 
Therefore, our findings suggest that although metabolic changes are likely to be 
involved, they cannot fully explain our observations. We cannot provide data on the 
expression of these cytokines on liver tissue, since repeat liver biopsies were not done 
due to ethical and economical reasons; therefore the mechanism linking changes in body 
weight to portal hypertension remain an open field for future studies. Pure NASH-
related cirrhosis (without other concomitant etiologic factors) was present in one fourth 
of patients included in this study. This small sample size did not allow us providing data 
regarding a possible (and likely) more marked effect of LS intervention on portal 
pressure in this etiology. 
 
Another limitation of the study is that we cannot assess whether the benefit of the life-
style intervention would be maintained, improved or lost over a long-term follow-up, as 
the observation period was limited to the 4-month of life-style intervention plus 6 
months of follow-up. It is possible that the beneficial effect hereby reported fades over 
time in case of new increase in body weight and/or sedentary life; however, it is equally 
likely that reiterated intervention might maintain the beneficial effect. It is worth noting 
in this regard that the success of the program in terms of achieving a body weight loss 
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of >5% exceeded all expectations (mostly derived from the obesity/diabetes field). It is 
likely that the excellent attendance and adherence to the program was partly due to the 
its intensive nature (with 10 nutritionist visits over 4 months and weekly sessions with a 
personal trainer) but we believe largely reflect the marked benefits on the perceived 
quality of life reported by the patients, which is likely to explain why the weight loss 
persisted unmodified during the 6 months of follow-up. Future studies should address 
whether new electronic tools such as electronic Fitness trackers (bracelets, watches, or 
clip-ons) might help in maintaining a good adherence to lifestyle changes lifelong. 
 
In conclusion, an intensive 16-week programme of tailored diet and moderate exercise 
can be safely recommended to obtain weight loss and HVPG decrease in 
overweight/obese patients with compensated cirrhosis and portal hypertension, and can 
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Figure 1. Effects of the intensive lifestyle intervention on body weight in the study 
population. As shown, a significant decrease was achieved, and 52% of patients 
showed a body weight decrease ≥ 5% (a priori defined as “clinically relevant”).  
Figure 2. Effects of the intensive lifestyle intervention on HVPG in the study 
population. As shown, a significant decrease was achieved, and 42% of patients 
showed a HVPG decrease ≥ 10% (a priori defined as “clinically relevant”). 
Figure 3. Percentage of change in HVPG according to the percentage of change in 
body weight. As shown, patients with weight loss over 10% showed a more 
pronounced decreased in HVPG, while patients in whom body weight did not change or 
increased did not show any change in HVPG. * indicates p <0.05 vs. baseline values. 
Figure 4. Graphical summary of the hypothetic effect of lifestyle intervention on 
HVPG in patients with cirrhosis and obesity. 
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       Age, yrs 56 ± 8 56 ± 8 56 ± 8 0.841 57 ± 7 55 ± 9 0.318 
Males, n (%) 31 (62%) 15 (58%) 16 (67%) 0.570 16 (76%) 15 (52%) 0.139 
      Etiology of cirrhosis, 















Gastroesophageal Varices present, n (%) 33 (66%) 16 (62%) 17 (71%) 0.559 12 (57%) 21 (72%) 0.366 
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Previous variceal bleeding, n (%) 15 (30%) 7 (27%) 8 (33%) 0.760 6 (29%) 9 (31%) 1.000 
On chronic non-selective beta-blockers, % 30 (60%) 16 (67%) 14 (58%) 1.000 11 (52%) 19 (66%) 0.393 
HVPG, mmHg 
% with HVPG≥10 mmHg  
13.9 ± 5.6 
72 
13.3 ± 5.0 
69 




14.9 ± 6.2 
71 




Child class A, % 92 92 92 1.000 90 93 1.000 
Platelet count, n*10
9
/mmc 106±48 103±41 110±55 0.615 96±31 113±57 0.223 
Glucose, g/dl 124±48 112±28 136±61 0.084 120±65 126±32 0.669 
AST, U/L 48±41 49±38 47±45 0.837 50±39 47±43 0.758 
ALT, U/L 44±37 44±37 43±37 0.928 47±40 41±34 0.594 
Bilirubin, mg/dl 1.1±0.6 1.1±0.6 1.1±0.5 0.985 1.1±0.6 1.1±0.5 0.867 
Albumin, g/L 36±5 37±5 36±5 0.492 36±5 37±5 0.548 
International Normalised Ratio 1.19±0.20 1.22±0.22 1.18±0.18 0.564 1.24±0.22 1.17±0.18 0.223 
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Creatinine, mg/dl 0.73±0.14 0.74±0.12 0.72±0.15 0.712 0.73±0.15 0.73±0.12 0.955 
MELD score 9±3 9±3 9±2 0.727 9±3 9±2 0.438 
MAP, mmHg  92±13 91±14 94±12 0.412 90±13 94±13 0.423 
Heart Rate, beats per minute 66±13 66±14 66±11 0.792 64±12 67±13 0.369 
Body weight, Kg (range) 
 
91.5 ± 13.9 
(64.4-118.4) 
 
91.4 ± 15.8 91.6 ± 11.7 0.957 93.2 ± 14.1 90.2 ± 13.7 0.456 
BMI, Kg/m2 (range)  
 
BMI 26-29.9 (Overweight), n (%) 
BMI 30-34.9 (Class I obesity), n (%) 
BMI 35-.39.9 (Class II obesity), n (%) 





33.2 ± 3.3 33.3 ± 3.1 0.970 33.0 ± 3.2 33.4 ± 3.2 0.618 








0.810 114 ±10 114 ±12 
 
0.947 
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Women 106±1 
% Fat Mass 
Men 
Women  
37.8 ± 7.6 
35.6 ± 7.7 
 41.4 ± 6.0 
38.7 ± 6.6 
 
36.7 ± 8.4 
 
0.389 34.5 ± 8.0 
 
40.1 ± 6.3 
 
0.013 
Completely sedentary lifestyle, n (%) 32 (64%) 17 (65%) 15 (62%) 0.772 12 (57%) 19 (66%) 0.570 
Daily intake of sugar drinks, n (%) 20 (40%) 8 (31%) 12 (50%) 0.248 9 (43%) 11 (38%) 0.776 
Estimated daily caloric intake, kCal  
Men 
Women 
2100 ± 450 
2265 ±400 
1800 ± 380 
2080 ± 460 
 
2120 ± 440 
 
0.752 2140 ± 430 
 
2080 ± 470 
 
0.650 
Diabetes mellitus, n (%) 21 (42%) 6 (23%) 15 (63%) 0.009 7 (33%) 14 (48%) 0.387 
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% of each treatment (% refers to 
diabetic patients) 
5/57/10/5/23 17/33/17/0/33 0/67/7/7/20 14/57/0/14/140/57/14/0/28 
History of arterial hypertension, n (%) 23 (46) 11 (42%) 12 (50%) 0.777 9 (43%) 14 (48%) 0.778 
Treatment for art. hypertension , n  18 8 10 0.640 8 10 0.610 
History of Dyslipidemia, n (%)  8 (16) 4 (15%) 4 (17%) 1.000 3 (14%) 5 (17%) 1.000 
Treatment for dyslipemia, n 5 
(Simvastatin in 
all) 
1 4 0.142 2 3 1.000 
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Table 2. Results of the variables object of the study before and after 16 weeks of intensive lifestyle intervention. 




HVPG, mmHg 13.9±5.6  12.3±5.2 <0.0001 
Heart rate, bpm 66±13 63±13 0.031 
Hepatic Blood Flow, ml/min* 898±520 782±382 0.565 
Indocyanine green extraction index, 
% 
54±17 59±19 0.048 
Systolic arterial pressure, mmHg 127±18 125±18 0.283 
Diastolic arterial pressure, mmHg 71±11 70±9 0.637 
Mean arterial pressure, mmHg 90±12 88±11 0.393 
Body weight, Kg 91.5±13.9 86.5±13.6 <0.0001 
Waist Circumference, cm 114 ±11 107±12  <0.0001 
Fat Mass, Kg 35.1±9.1  30.2±8.3  <0.0001 
Lean Mass, Kg 56.7±11.2  55.6±12.7  0.340 
Total Cholesterol (mg/dl) 161±34 149±34 <0.0001 
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Tryglicerides (mg/dl) 105±88 86±33 0.147 
Glucose, mg/dl 124±48 118±48 0.406 
HOMA 9.5±9.4 6.1±4.8 0.015 
QUICKI 0.29±0.03 0.31±0.04 0.008 
Child score 5.5±0.7 5.6±0.9 0.229 
MELD score 9.0±2.6 9.4±2.8 0.152 
Albumin, g/L 37±5 36±5 0.387 
Bilirubin, mg/dl 1.13±0.55 1.17±0.71 0.482 
INR 1.20±0.20 1.20±0.21 0.711 
Creatinine, mg/dl 0.73±0.13 0.73±0.19 0.889 
Platelet count, 10
9
/L 106±48 105±56 0.793 
Oxygen uptake-VO
2
, mL/kg/min** 21.3±7.4 25.7±9.3 <0.0001 
Plasma insulin, pg/ml  912±726 670±506 0.002 
Plasma leptin, ng/ml  29.7±18.3 20.3±12.7 <0.0001 
 
* available in 23 of the included patients. ** available in 24 of the included patients. 
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Table 3. Percentage HVPG Change after 16 weeks of LS intervention according to the amount of BW reduction and to the amount of 
exercise performed (METs). Data refer to the 39 patients in whom physical activity could be quantified. Data are expressed both as median 
(interquartile range). Non-parametric tests were used to obtain the p value.  
HVPG Decrease 
 Exercised above median Exercised below median P 
 
BW Decrease >10% - 16.3 (N/A) (n=3) 
 
- 24.3 (47.7) (n=4) 
 
0.582 
BW Decrease 5-10% -8.7 (15.5) (n=8) 
 
0 (13.2) (n=9) 
 
0.196 
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Supplementary Methods 
Measurement of Adipokines, adipocytokine and cytokines: – A commercial 
multiplexed bead-based immunoassay Milliplex MAP Human Adipokine Magnetic 
Bead Panel 2 (HADK2MAG-61K, Merck Millipore, Darmstadt, Germany) was used to 
simultaneously measure the following 9 biomarkers in serum on a Luminex 100 
Bioanalyzer (Luminex Corp., Austin, TX): Interleukin 6 (IL-6); Interleukin 8 (IL-8), 
Interleukin 1beta (IL-1b), Insulin, Leptin, Hepatocyte Growth Factor (HGF), Tumor 
Necrosis Factor alpha (TNF-a), Nerve Growth Factor (NGF) and Monocyte 
Chemoattractant Protein 1 (MCP-1). The readouts were analyzed with the standard 
version of the Milliplex Analyst software (Merck Millipore). A five-parameter logistic 
regression model was used to create standards curves (pg/mL) and to calculate the 
concentration of each sample. 
Human adiponectin levels were determined in 25 ml of serum using the specific ELISA 
kit EZHADP-61k (Merck Millipore). 
 
Hepatic Venous Pressure Gradient. In the morning, after fasting overnight, patients were 
transferred to the hepatic hemodynamic laboratory. Under local anesthesia, a 8F venous 
catheter introducer was placed in the right internal jugular vein using the Seldinger 
technique. Under fluoroscopic control a 7F balloon-tipped catheter (Edwards 
Lifesciences, Irvine, CA, USA) was advanced into the right hepatic vein to measure 
wedged and free hepatic venous pressures using pre-calibrated electro-mechanical 
transducer and polygraph (Mac-Lab®, GE Healthcare, Freiburg, Germany). The 
wedged position was obtained by inflating the balloon and confirming the occlusion of 
the hepatic vein by injecting a small amount of contrast medium. HVPG was calculated 
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as the difference between wedged and free hepatic venous pressures (1). All 
measurements were performed in triplicate and permanent tracings were recorded (1). 
The free hepatic vein pressure was measured at 1-3 cm of the ostium of the hepatic vein 
into the inferior vena cava (1). 
Hepatic blood flow. 
A subgroup of 23 patients (those included in two of the participating centers: one center 
in Barcelona and one center in Madrid) underwent measurement of hepatic blood flow 
through indocyanine green clearance method. Preceded by a priming dose of 5 mg, a 
solution of indocyanine green (Pulsion Medical Systems, Munich, Germany) was 
infused intravenously at a constant rate of 0.2 mg/min. After an equilibration period of 
at least 40 minutes to achieve a steady-state, 4 separate sets of simultaneous samples of 
peripheral and hepatic venous blood were obtained for the measurement of hepatic 
blood flow according to the Fick’s method as previously described. To avoid 
interferences from differences in plasma turbidity, the Nielsen’s correction was used at 
the moment of reading ICG concentration in the samples by spectrophotometry (SP-
830, Turner Biosystems, Sunnyvale, CA, USA).  
Briefly, ICG clearance was calculated as ICG constant infusion velocity/mean 
concentration of ICG in the peripheral venous blood. ICG extraction index was 
calculated as: (concentration of ICG in the peripheral venous blood – concentration of 
ICG in the hepatic venous blood)/concentration of ICG in peripheral venous blood. 
Hepatic plasma flow was estimated as ICG clearance/ICG extraction index. Finally, 
hepatic blood flow was estimated as: hepatic plasma flow /(1- hematocrit) (2). 
Nutritional status assessment. Patients were asked to fill-in a 3-days log (2 working 
days and 1 week-end day) regarding their dietary habits, which was assessed by a 
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experienced nutritionist in order to calculate the baseline food intake of the patient (total 
Kcal, grams and % of carbohydrates, lipids and proteins; water intake; fiber intake in 
grams). The following anthropometric measures were also recorded: waist 
circumference, body weight. Bioelectrical impedance analysis method was used to 
assess lean/fat mass (Tanita body composition analyzer, Model BC-148 MA, Tanita 
Corp., Tokyo, Japan). 
Physical activity assessment. Patients were asked specific questions regarding whether 
they used to perform exercise, and in case they did regarding its kind, intensity and 
duration; specific questions regarded sedentarism (number of hours spent watching TV 
or computer). Evaluation of maximal oxygen consumption (VO2) was performed by the 
Bruce test in 24 patients, all included in Barcelona. 
Quality of life 
A liver-disease specific validated questionnaire was used (CLDQ, Spanish edition)(3). 
Patients filled-in autonomously the questionnaire, which contains questions regarding 6 
domains of quality of life (abdominal symptoms, fatigue, systemic symptoms, activity, 
emotional function, worry). Score for every question is an entire number between 0 (the 
worst possible) and 7 (the best possible). 
Lifestyle intervention 
An intensive lifestyle intervention was initiated within one week of the baseline HVPG 
measurement. It consisted in 16-week of caloric restriction (diet) and exercise, which 
are detailed below.  
Diet: consisted in a tailored reduction in caloric intake of 500-1000 kCal per day 
(according to the European Food Information Council this kind of diet allows a weight 
loss of 0,7 - 1,4 Kg per week, sufficient to achieve a clinically relevant weight loss). 
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Tailoring consisted taking into account the alimentary preferences and preferred intake 
hours of each patient, in order to maximize adherence. Protein intake was maintained 
between 20 and 25% of the total intake in order to reduce the risk of muscle mass loss, 
but within 0.8 g/Kg of ideal BW (calculated for a BMI=25 Kg/m2)/day. Diet was 
balanced in order to be not ketogenic, and as varied as possible. Carbohydrates 
accounted for 45-50% of total kCal, fat content was maintained < 35% of total kCal, 
and 20 g of alimentary fiber was also recommended. No alcohol was allowed. The 
nutritionist provided to patients examples of food schemes (usually 3 major meals and 2 
snacks), also indicating food that could be exchanged with other with similar nutritional 
content, and asked patients to monitor weekly their BW, at home or in a pharmacy, in 
order to increase their awareness. After the first visit patients were followed-up by the 
nutritionist once a week for the first month (intensification period), and every two 
weeks thereafter. At each visit patients were given a new three-day nutritional log to be 
filled-in in order to increase their awareness regarding food intake. This was checked by 
the nutritionist during the next follow-up visit; data were entered a software (Dietsource 
3.0 ® Nestle Healthcare Nutrition S.A., Vevey, Switzerland) that allows quantifying 
caloric intake.  Assessment of adherence to diet was performed by a subjective tool 
(visual analogue scale) and by an objective quantification as follows: 
adherence in percentage = [100- (real calculated caloric intake - recommended 
intake/recommended intake)*100].  
At the end of each visit the nutritionist gave verbal positive reinforcement about dieting 
and exercising. 
Physical activity: On the same week of nutritional intervention initiation, patients began 
exercising. Exercise was supervised by two professional trainers (PTs), one for patients 
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included in Barcelona and one for patients included in Madrid. One weekly 60 minutes 
session of moderate exercise in small groups (1-5 patients) was conducted. Every 
session consisted in 10 minutes of warm up, 40 minutes of aerobic and strength 
exercising routine, and 10 minutes of cooling down. Exercise routine was chosen by the 
trainers avoiding abdominal workouts/pump, and tailored to a perceived exertion of 4-
5/10 (Visual Analogue Scale) or 10-12 Borg Rating of Perceived Exertion Scale. 
A subgroup of patients (n=24, all included in Barcelona) underwent assessment of 
maximal oxygen uptake (VO2max) by a standard Bruce’s test based on progressive 
effort on a treadmill at baseline and 16-wks. 
In addition, all patients were instructed to increase their daily standard physical activity, 
e.g. by walking at least 30 minutes, and progressively as long as possible, and/or by 
swimming or biking. The PTs suggestion was to avoid excessive efforts, defined as > 
6/10 of that perceived subjectively. Patients were given an exercise log to fill-in every 
day to increase their awareness and adherence. The PTs reviewed each patient’s log at 
every weekly session and gave verbal positive reinforcement of the importance of 
maintaining and improving daily physical activity. 
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Supplementary Table 1. Unsupervised physical activity per week and over the entire LS 
intervention in the study subgroup with available data (n=39). Data is shown as median (minimum-
maximum). 
Activity Median Hours/week 
(min-max) 
Overall Hours spent 





Walking (all patients, n=39) 5.1 (1.9-14.3) 97.9 (43.0-241.0) NA 
Subgroup performing other physical 
activities (n=16) 
Cycling: n=10, swimming n= 2, jogging 
n=1 and mixed aerobic/anaerobic 
activity n=3 
2 (0.5-8) 30 (4-151) NA 
Total walking or exercising over 16 
weeks (n=39) 
NA 123.7 (43-241) 400.5 (150.5-1032.9) 
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Appendix 
Ciberehd SportDiet Collaborative Group: Hospital Clinic, Barcelona: Hepatologists: Annalisa 
Berzigotti; Jaume Bosch; Juan Carlos García-Pagán; Juan G. Abraldes; Joan Caballería; Jordi 
Colmenero; Alejandro Forner; Enric Reverter; Susana Seijo; Nutritionists: Violeta Moize, Alba 
Andreu; Nurses at Hepatic Hemodynamics Laboratory: Angels Baringo, Laura Rocabert, Rosa 
Saez, Lara Orts; Biochemists: Joan Claria, Esther Titos. Hospital Santa Creu i Sant Pau, 
Barcelona: Hepatologists: Candid Villanueva; Alba Ardevol; Isabel Graupera; Nutritionists: Pilar 
Ulldemolins; Amelia Romero. Hospital  Universitari Vall d’Hebron, Barcelona: Hepatologists: 
Joan Genescá; Salvador Augustín; Nutritionist: Guillermo Cardenas; Research nurse: Laura Millán. 
Personal Trainer for all the patients included in the three Centers in Barcelona: Marco Mangone. 
Hospital Univ. Ramón y Cajal, Madrid: Hepatologists: Agustín Albillos; Francisco Mesonero. 
Hospital Puerta de Hierro, Madrid: Hepatologists: Jose Luis Calleja; Elba Llop. Hospital 
General Universitario Gregorio Marañon, Madrid: Hepatologists: Rafael Bañares; Cristina 
Ripoll; Javier García-Lledó 
Nutritionist and Personal Trainer for the patients included in the three Centers in Madrid: Belén 
Rodríguez 
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Supplementary Figure 1. Diagram illustrating the study design. 
Supplementary Figure 2. Individual changes in Body weight obtained the intensive LS 
intervention. The red line indicates the average value of the studied population:  from 91.5±13.9 
Kg to 86.5±13.6 Kg (p<0.0001). 
Supplementary Figure 3. Individual changes in HVPG obtained the intensive LS 
intervention. The red line indicates the average value of the studied population: from 13.9±5.6 
mmHg to 12.3±5.2 mmHg (p<0.0001). 
Supplementary Figure 4. Effects of the intensive LS intervention on the different domains 
of CLDQ.  
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